12:00 AM
 | 
Nov 02, 2009
 |  BC Week In Review  |  Company News  |  Deals

Idenix, Novartis deal

Novartis' Novartis Pharma AG unit did not exercise its option to license IDX184 from Idenix. The liver targeted prodrug of 2'-methyl guanosine monophosphate...

Read the full 93 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >